Head and neck radiation trial removes a long-standing safety margin
City of Hope is preparing a pilot study that asks a focused question in head and neck squamous cell carcinoma: can definitive radiation be delivered safely without the planning tumor volume, or PTV, and still preserve locoregional control? The trial is designed around the idea that modern image guidance and intensity-modulated planning may have already narrowed the need for the geometric buffer that has traditionally surrounded the target. In the clinic, that buffer exists for a reason — it compensates for setup variation, patient motion, and day-to-day uncertainty in how the beam lands. But it also expands the dose spill into normal mucosa, salivary tissue, swallowing structures, and laryngeal anatomy, which are the very tissues that drive much of the acute and late morbidity after treatment.
The protocol, titled Pilot Study of the Elimination of Planning Tumor Volume (PTV) in Head and Neck Squamous Cell Carcinoma, plans to enroll 30 patients and is listed as not yet recruiting. Estimated study start is June 22, 2027, with primary and final completion both projected for December 22, 2028. The population spans multiple head and neck sites and stages, including HPV-mediated oropharyngeal disease and non-HPV-related cancers of the hypopharynx, larynx, and oropharynx. By bringing those groups into one feasibility framework, investigators are testing whether tighter conformality can be generalized across a broad but still anatomically complex disease set.
Radiation planning in head and neck cancer has always balanced precision against uncertainty. The PTV is the margin that tries to absorb that uncertainty.
Why removing the margin could matter at the bedside
The biological rationale for the study is straightforward. The tumor itself sits inside a clinical target volume that accounts for visible disease and probable microscopic spread. Around that, the PTV adds another layer to protect against a miss. When treatment accuracy improves through image guidance and daily verification, the normal tissue included in the high-dose region may become a modifiable exposure rather than an unavoidable one. In a disease where swallowing dysfunction, mucositis, xerostomia, odynophagia, aspiration risk, dysphonia, and feeding-tube dependence can dominate recovery, even modest reductions in dose to adjacent structures could translate into meaningful differences in early symptom burden and longer-term function.
The protocol’s primary objectives reflect that dual concern for cure and toxicity. Investigators will describe the effect of eliminating PTV on locoregional control and marginal recurrence at 6 months in patients receiving definitive radiation, with or without concurrent chemotherapy. They will also examine early toxicity, patient-reported outcomes, and quality of life. The short-term endpoint is important because if the margin is removed, the first concern is not abstract dosimetry; it is whether tumor cells at the edge of the treated volume begin to escape control in the months after therapy. A marginal failure would be a direct signal that the geometric safety net was doing essential oncologic work.
Daily image guidance replaces a geometric cushion
Treatment on study uses either intensity-modulated radiation therapy or image-guided radiation therapy without PTV, delivered 5 to 6 times per week for 35 fractions over 6 to 7 weeks. Concurrent chemotherapy is permitted. That schedule places the trial squarely in the definitive setting, where local control depends on accurate dose placement across a protracted treatment course and where cumulative toxicity can rise quickly if oral cavity, pharyngeal constrictors, spinal cord-adjacent tissues, or salivary glands receive excessive exposure.
Screening includes computed tomography, FDG-PET/CT, and laryngopharyngoscopy. Follow-up imaging with CT or FDG-PET/CT continues after treatment, alongside serial clinical reassessment every 3 months during years 1 and 2 and every 6 months during years 3 through 5. Those intervals make sense for head and neck cancer, where early recurrence risk is front-loaded and where late effects can evolve slowly after the last fraction is delivered. The protocol also builds in patient-reported outcomes and quality-of-life assessment, an important choice because the lived burden of treatment in this disease is often missed if the focus stays only on disease control.
The study’s secondary objectives extend the same question over a longer horizon. Investigators will examine locoregional control at 2 and 5 years, patterns of failure at 3 months, 2 years, and 5 years, later toxicity, later patient-reported outcomes, and dosimetric differences between plans with and without PTV. They will also track marginal recurrence at 2 and 5 years. The longer follow-up is critical because a strategy that appears acceptable at 6 months can still fail later if microscopic disease emerges at the edge of the target or if late toxicity accumulates despite an early clean bill of health.
A small pilot with a large planning question
The estimated enrollment of 30 patients makes this a pilot study, not a definitive practice-changing trial. Even so, pilot studies can reshape the next layer of protocol design when the underlying question is anatomical and technical rather than pharmacologic. Head and neck radiation is one of the most technically demanding areas in oncology, with a dense cluster of tumor-adjacent normal structures and constant concern for small setup deviations that can have outsized clinical effects. If the margin proves unnecessary in carefully selected patients treated with modern image guidance, the field could move toward less collateral exposure without sacrificing the core goal of durable tumor control.
On the other hand, if marginal recurrence appears in a pattern tied to omission of the PTV, the study would reinforce why that geometric buffer has remained standard for so long. Either result would be clinically meaningful because it tests the logic of contemporary radiation planning against real disease behavior rather than against planning theory alone.
For now, the trial is a carefully defined attempt to answer a practical oncology question: whether improved targeting technology has finally advanced enough to trim away a margin that has long been considered essential. The answer will depend on recurrence patterns, toxicity, and patient-reported recovery over months and years, not on planning elegance alone.
What remains unresolved is whether tighter conformality can preserve the same oncologic safety across HPV-mediated and non-HPV-related disease, and whether the expected dosimetric gains will be large enough to change the symptom burden that patients actually feel during and after treatment.